Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.Science Translational Medicine|April 29, 2011
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cellsMarcus O Butler, Philip Friedlander, Matthew I Milstein, et al.Cancer Immunology Research|May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanomaF Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.Cancer Discovery|March 17, 2025
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant SettingMansi Saxena, Thomas U Marron, Julia Kodysh, et al.Pageof 3